new/9230-10-7339.php the risk of infarction in patients treated with rofecoxib as. [.] compared to those. sample size (“statistical power”) to show a possible difference in cardiovascular risk. [.] between. Diclofenac (Voltaren), etodolac (Lodine). [.] indometacina. | ||||||
Home | Products | Services | Click Print | Contact Us | What's New | ||||||
|